Background: Children with red blood cell disorders may receive regular transfusions from an early age and consequently accumulate iron. Adequate iron chelation therapy can prevent organ damage and delayed growth/development. Deferasirox is indicated for treatment of pediatric patients with chronic iron overload due to transfusional hemosiderosis; however, fewer than 10% of patients in the registration studies were aged 2 to less than 6 years.
INTRODUCTION
Children with inherited red blood cell disorders, such as -thalassemia, sickle-cell disease (SCD), and Diamond-Blackfan anemia (DBA), may receive regular transfusions from an early age as supportive therapy.
Iron overload is an expected consequence of regular red blood cell patients with a range of underlying transfusion-dependent conditions, including -thalassemia, SCD, and DBA. [6] [7] [8] [9] With appropriate dosing based on iron intake, efficacy, and safety parameters, deferasirox reduced the total body iron burden for up to 5 years. 10, 11 Deferasirox had a manageable safety profile with respect to laboratory parameters and adverse events (AEs). The most frequently reported AEs over 5 years were transient, mild-to-moderate gastrointestinal disturbances, skin rash, and increases in serum creatinine (SCr), the incidence of which decreased over time. Events rarely required drug discontinuation and most resolved spontaneously. Deferasirox has a mild effect on renal hemodynamics. 12 Increases in SCr, a renal function marker, are generally dose related and can be resolved with dose reductions or interruptions. 4, 5, 12 However, cases of deferasiroxinduced renal tubular acidosis have occurred. 13, 14 Monitoring alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin is also recommended to assess hepatic function. While hepatic dysfunction may occur, most increases in aminotransferase levels are not drug related and correlate with iron load. 5, 10, 15 Deferasirox treatment has been associated with liver fibrosis reversal or stabilization in most iron-overloaded patients with thalassemia. 15 However, abnormal liver function tests have been more frequently reported in children receiving deferasirox, 16 highlighting the necessity for close monitoring, particularly pediatric patients. Of the 1,005 patients enrolled in the registration studies, only 83 (8.3%) were 2 to less than 6 years old; therefore, further collection of efficacy and safety data in young patients was deemed necessary. In addition, for patients who cannot be cured with hematopoietic stem cell transplantation, requirements for transfusions with chelation therapy may be lifelong. Furthermore, intensive chelation therapy with parenteral deferoxamine in young patients (<3 years old) has been associated with growth retardation. 17 As such, continual assessment of outcomes of supportive therapy are valuable, supplementing data from the deferasirox registration studies and extensions in patients with -thalassemia 10 and SCD. 11 The 5-year ENTRUST study assessed long-term safety of deferasirox in young pediatric patients with transfusional hemosiderosis in everyday clinical practice as part of the active postapproval deferasirox surveillance program.
METHODS

Study design and patient population
Male and female patients aged 2 to less than 6 years with transfusional hemosiderosis, eligible for deferasirox treatment according to local prescribing information, were enrolled and followed prospectively for 5 years in this observational study (ENTRUST; ClinicalTrials.gov identifier: NCT00466063). Retrospective data were collected for patients who started on deferasirox less than or 12 months prior to enrollment (i.e., data were collected from the start of deferasirox treatment for 5 years). Patients were excluded if they were involved in other iron chelator trials.
The study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki and was approved by independent ethics committees at participating sites. Patients' parents/guardians provided written, informed consent prior to enrollment.
Deferasirox dosing and iron intake
Patients were treated with deferasirox and monitored in accordance with local (country-specific) deferasirox prescribing information. As such, there was no therapy protocol, diagnostic or therapeutic intervention outlined, or strict visit schedule. In summary, initial deferasirox dose was 10-30 mg/kg body weight based on country-specific prescribing information, with recommendations to adjust dose according to serum ferritin levels, therapeutic goals, tolerability, and patient weight changes. Total and average amount of blood transfused and average iron intake during the observation period were recorded. Compliance was assessed at retrospective interviews.
Assessments
The co-primary endpoints were as follows: the proportion of patients (within a maximum of 5 years' observation) with SCr over the ageadjusted upper limit of normal (ULN) and more than 33% from baseline on two or more consecutive postbaseline measurements taken 7 or more days apart; and the proportion of patients with ALT levels higher than five times the ULN in two or more consecutive postbaseline measurements taken 7 or more days apart. Secondary endpoints included monthly serum ferritin levels (surrogate marker for body iron levels) to assess long-term deferasirox effectiveness.
Safety was evaluated by regular monitoring and recording of AEs and serious AEs (SAEs), laboratory testing, and clinical evaluations. Particular attention was given to collection of SCr, creatinine clearance (CrCl; calculated), urea, liver aminotransferases, bilirubin, alkaline phosphatase, and proteinuria data; blood pressure; auditory and ophthalmological assessments; and growth and sexual development.
Sample size and statistical analysis
Assuming a 20% dropout rate, a 200-patient sample size at registry end was proposed so that a two-sided 95% confidence interval (CI) would extend 0.03 from the observed proportion for a true probability of 0.05. Safety was evaluated in all patients who received one or more deferasirox dose during the study, with one or more postbaseline safety assessment (safety set). The full analysis set (FAS) consisted of all patients who received one or more deferasirox dose during the study and was used for efficacy analyses. The primary endpoints were estimated together with two-sided 95% CIs. Descriptive statistics were used for continuous variables and frequency was used for categorical variables. a Hb E/ -thalassemia (n = 7), -thalassemia (n = 6), hereditary spherocytosis (n = 5), congenital dyserythropoietic anemia (n = 2), hemolytic anemia (n = 1), hemoglobin Hakkari (n = 1), hereditary erythroblastic multinuclearity with positive acidified serum lysis test (n = 1), myelodysplasia (n = 1), Shwachman-Diamond syndrome (n = 1), X-linked sideroblastic anemia (n = 1), pyruvate kinase deficiency (n = 1). b Patients outside of the age range for enrollment per protocol.
RESULTS
Patient demographics and clinical characteristics
In total, 269 patients were enrolled between May 9, 2007, and July 31, 2015, across 65 sites worldwide; two patients did not receive deferasirox and were excluded from the FAS. Inclusion of additional patients was approved by the data monitoring committee. Most had -thalassemia major (n = 176, 65.9%) and serum ferritin levels higher than 1,000-2,500 ng/ml (n = 182, 68.2%; Table 1 ). A total of 198 patients (74.2%) were newly started on deferasirox. Five years of follow-up was completed by 145 patients (54.3%), who had safety data collected during this entire period. The main reasons for discontinuation (≥5% of patients) were "other" (n = 55, 20.6%; including but not limited to family travel, not being able to afford medication, poor compliance, and bone marrow/stem cell transplantation), loss to follow-up (n = 19, 7.1%), and AEs (n = 18, 6.7%; of which n = 16 were suspected to be deferasirox related by the investigator; most commonly increased ALT and increased AST, n = 7 each). Overall, annual discontinuation rates over 5 years of follow-up were 36 (13.5%), 34 (12.7%), 25 (9.4%), 14 (5.2%), and 13 (4.9%), respectively.
Deferasirox dosing and exposure
During the study, patients received a mean ± standard deviation (SD) 
Average iron intake
Most patients experienced frequent blood transfusions, with 172 patients (64.4%) receiving at least 7 ml/kg per month. Average iron intake was recorded in 229 patients (85.8%): less than 0.3 mg/kg per day in 93 patients (34.8%), 0.3-0.5 mg/kg per day in 115 patients (43.1%), and more than 0.5 mg/kg per day in 21 patients (7.9%).
Long-term safety of deferasirox 3.4.1 Laboratory parameters
Mean SCr levels increased as expected in a pediatric patient population from 28 mol/l at baseline to 39.4 mol/l at the end of study (EOS; Fig. 1A ). The proportion of patients with SCr greater than the age-adjusted ULN on two or more consecutive postbaseline measurements, 7 or more days apart, was 4.4% (95% CI: 2.1-7.9). Two consecutive SCr increases to greater than the age-adjusted ULN and more than 33% compared with baseline occurred in eight patients (3.1%). In two of these patients, deferasirox dose was decreased, SCr levels normalized, and the patients completed the study. In the other six patients, deferasirox dose was not adjusted; four patients completed the study Among evaluable patients during the 5-year observation period, CrCl was consistently 90 ml/min or higher in 185 patients (70.9%). Thirteen patients (5.0%) had confirmed CrCl 60 to less than 90 ml/min at least once during the study. No patient had confirmed CrCl less than 60 ml/min.
Mean ALT levels showed a slight increase within the first 6 months, followed by a steady decline over time (Fig. 1B) . The proportion of patients with ALT more than five times the ULN on two or more consecutive postbaseline measurements, 7 or more days apart, was 4.0% (n = 9; 95% CI: 1.8-7.4). In total, 74 patients (28.4%) entered the study with ALT levels higher than the ULN, 43 (58.1%) of whom achieved ALT levels less than or equal to the ULN by EOS. In all, 31 patients (11.9%) received deferasirox dose adjustments or interruptions because of elevated ALT and seven (2.7%) discontinued treatment because of ALT increases. Overall, 11 patients (4.2%) had two consecutive ALT increases more than five or more than 10 times the ULN, three of whom received dose interruptions accordingly. Although simultaneously increased ALT or AST levels more than three times the ULN and total bilirubin levels more than two times the ULN were occasionally observed, there were no cases that fulfilled the criteria of Hy's law. 18 
TA B L E 2
Most common investigator-assessed drug-related AEs (occurring in four more patients) by preferred term overall and by annual inci-
Gastrointestinal disorders
Vomiting 14 (5.4) 8 (3.1) 6 (2.3) 3 (1.1) 1 (0.4) 3 (1.1) Abdominal pain 8 (3.1) 3 (1.1) 3 (1.1) 1 (0.4
Adverse events
In the safety set, AEs regardless of relationship to deferasirox were reported in 217 patients (83.1%) during the 5-year observation period.
There was a gradual decrease in the number of patients experienc- AEs with a suspected relationship to deferasirox were reported in 102 patients (39.1%) and were predominantly related to abnormal liver enzyme levels ( Table 2) . Of the 55 patients with reported increases in ALT levels suspected to be deferasirox related, 20 entered the study with ALT levels more than 40 U/l and two had a history of gallstones.
Nine patients (3.4%) were reported with SAEs suspected to be deferasirox related: increased liver aminotransferases (n = 3), hepatocellular injury (n = 2), vomiting/abdominal pain (n = 1), renal tubular disorder (n = 1), upper gastrointestinal bleed (n = 1), and hematuria/gastroenteritis (n = 1). Of these, six patients discontinued the study because of AEs. No patient had a fatal outcome while under observation.
Auditory and ophthalmological assessments
Of 153 patients with postbaseline auditory reports, 15 (9.8%) reported an AE related to ear and labyrinth disorders (most commonly, conductive deafness [n = 8, 5.2%] and ear pain [n = 3, 2.0%]). These were transitory and usually associated with upper respiratory or middle ear infections. There were 21 patients (13.7%) with evidence of hearing impairment in at least one ear, none of which were suspected to have any relationship to deferasirox. There was one case of mild neurosensory deafness with a suspected relationship to deferasirox.
The patient was lost to follow-up and the event was ongoing at EOS.
Of 168 patients with postbaseline ophthalmological reports, 12 (7.1%) had an AE related to eye disorders, although none were considered study drug related. Two patients had an abnormal ophthalmological examination. One case of mild ocular icterus occurred, not suspected to be deferasirox related. The patient did not receive dose alterations and discontinued the study because of low serum ferritin levels. A subcapsular cataract was reported with suspected relationship to deferasirox, although the patient did not have a baseline ocular examination or any relevant ocular medical history recorded.
Deferasirox dose was not adjusted and the patient completed the study.
Growth velocity, height, and weight assessments
Mean growth velocity was 4.9-6.0 cm per year in male and 5.4-6.1 cm per year in female patients (Supplementary Table S1 ), as observed across all geographical regions. Mean weight also increased steadily over time (Supplementary Table S1 ), in line with mean growth velocity. One patient with -thalassemia major experienced an AE of below normal height that was not suspected to be drug related.
Long-term efficacy of deferasirox
Median serum ferritin levels decreased from 1,702 ng/ml (range 334-9,577) at baseline (n = 243) to 1,127 ng/ml (range 38-6,428) at 5 years (n = 84), although there were slight increases at the start and toward the end of the observation period (Fig. 2) . These observations 
DISCUSSION
This study reports the safety profile of deferasirox over 5 years in young children aged 2 to less than 6 years at enrollment, with chronic iron overload related to blood transfusions. These long-term findings in the largest formal study of deferasirox therapy in young pediatric patients support previously reported 1-year safety and efficacy data, 6-9 as well as longer term trials showing a decreasing annual AE incidence. 10, 11 Importantly, no new or unexpected safety findings were observed with regard to AEs or laboratory abnormalities, with a limited number of patient discontinuations as a direct result of AEs.
Although direct comparison between trials is precluded by differences in study design and patient demographics, the discontinuation rate was in line with that previously reported in thalassemia patients receiving deferasirox in a controlled clinical trial. 10 Furthermore, analyses from the present study indicate a decreasing trend in the number of patient discontinuations over time, reflecting successful patient management and treatment acceptance in clinical practice.
As patients in this observational study were treated in accordance with local prescribing information, pre-existing renal impairment represents a contraindication for deferasirox treatment. In this study, the renal safety profile was consistent with the known deferasirox safety profile. No patients exited the study because of renal dysfunction, and there was no evidence of irreversible renal damage. Renal abnormalities may occur in children treated with deferasirox. However, transfusion-dependent thalassemia patients may also develop renal dysfunction independent of deferasirox therapy. 19 Both iron overload and anemia likely contribute to renal dysfunction. 20, 21 In this study, the proportion of patients experiencing clinically relevant changes in renal hemodynamics during the 5-year observation period was low (4.4%), with few patients experiencing reduced renal function, consistent with previous studies. 10 Observed absolute SCr values showed a slight linear increase over time, without exceeding the age-adjusted ULN. This is consistent with the normal proportional increase in SCr and muscle mass 22 expected during continued growth for a pediatric population.
Importantly, these results show no indication of progressive worsening of renal function over time, which conforms with a Phase I study showing deferasirox to have only a mild, generally reversible hemodynamic effect. 12 The proportion of patients experiencing clinically relevant changes in hepatic function was also low (4.0%). Notably, almost a third of patients (27.6%) entered the study with ALT higher than the ULN, and many patients were iron overloaded at baseline according to serum ferritin levels; over half of these patients achieved ALT levels less than or equal to the ULN by the EOS. There was an initial increase in ALT levels followed by a downward trend over time, which was also observed in a previous 5-year analysis of deferasirox in adult and pediatric patients with -thalassemia. 10 Patients were managed according to the perceived risk by the investigator for deferasirox contributing to liver cell injury, with 12% of the patients receiving dose adjustments accordingly. Most patients who experienced ALT and/or AST increases continued deferasirox treatment at the same or reduced dose. The most frequently reported AE with suspected relationship to deferasirox was increased ALT alongside increased AST. In this observational study, the overall drug-related gastrointestinal disorders were less frequently reported than in previous studies, although it has been recently incorporated into the deferasirox label that children aged 2-5 years are at higher risk of experiencing diarrhea compared with the overall patient population. Therefore, further analyses of the current dataset are warranted and are ongoing.
Previous long-term studies of deferasirox in pediatric patients with -thalassemia and SCD 10, 11 have indicated that growth and sexual development are not impaired and progress normally. Owing to the young age of patients enrolled in this study, long-term effects of deferasirox therapy on sexual development could not be definitively assessed. However, annual growth velocity was as expected in this prepubertal patient population and was in line with public growth curves for children aged 2 to less than or equal to 11 years. Therefore, adequate deferasirox therapy does not appear to have an adverse effect on growth, confirming previous findings. 10, 11 The observed reduction in serum ferritin further supports deferasirox effectiveness in controlling and decreasing body iron, when used at an appropriate dose for the degree of iron overload and ongoing iron intake rate. The increase in total deferasirox dose from baseline to EOS was as expected for a growing population.
However, failure to adjust the deferasirox dose in some cases, despite substantial weight gain, likely affected the magnitude of change in serum ferritin over the 5-year period. These data highlight the need to adjust deferasirox dose based on increases in patient weight in order to provide optimal therapy.
Assessment of efficacy was limited to serum ferritin analysis in this study. Serum ferritin levels can be influenced by inflammatory processes, 23 which are often exacerbated in patients with SCD because of vaso-occlusive crises, hemolysis, and infection. 24 Serum ferritin levels in patients with SCD have shown varying degrees of correlation with liver iron concentration, a more direct measure of iron overload recommended for monitoring iron, particularly in SCD patients 25 and -thalassemia patients, 16 when available. Approximately 20% of the observed patients in this study had SCD, which likely confounded the efficacy outcomes based on serum ferritin assessments alone. Indeed, the slight increase in median serum ferritin levels at EOS was attributable to patients with SCD.
This study has several limitations. The study was limited by its observational nature, as well as the lack of a predefined therapy protocol, diagnostic/therapeutic interventions, and visit schedule. Therefore, this study did not determine if more aggressive therapy could result in a higher incidence of AEs.
Identifying an effective and tolerable chelator for young children, While the deferasirox safety profile in young children more than 2 years old appears similar to that in older children and adults, longterm effects on puberty, cataract formation, auditory, renal, and liver function after decades of drug exposure starting in early childhood have not been evaluated. Life-threatening, drug-related events are rare in more than 5,000 patients treated with deferasirox in clinical trials and many more in postmarketing monitoring.
Three iron chelators are available, with different routes of administration and potential side effects. 26 Deferoxamine requires parenteral infusions over 8 hr per day and is associated with visual, auditory, and renal dysfunction. 27 Two oral iron chelators, deferiprone and deferasirox, are approved by the US Food and Drug Administration (FDA). Deferiprone requires administration three times a day, and relatively common side effects include hepatic enzyme elevation, gastrointestinal discomfort, and arthralgias; agranulocytosis is an uncommon but potentially life-threatening side effect that resulted in a FDA black box warning and routine weekly white cell count monitoring. 28 Deferasirox, administered once daily with a safety profile outlined herein, has a FDA black box warning for rare, lifethreatening complications including renal failure, liver failure, and gastrointestinal hemorrhage; patients at most risk have comorbidities including advanced age, myelodysplastic syndromes, and preexisting renal and liver impairment. 5 While young children appear to be at lower risk of these life-threatening events, long-term follow-up studies are needed to determine their cumulative risk. All patients require close monitoring based on efficacy and safety guidelines.
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